Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.
Vaccinex, Inc. reports developments as a clinical-stage biotechnology company focused on investigational antibody therapies for neurodegenerative disease and cancer. Its lead program, pepinemab, is an anti-SEMA4D antibody being developed for Alzheimer’s disease and other neurological indications, with additional clinical work in cancer, including head and neck cancer and melanoma immunotherapy settings.
Company news commonly covers pepinemab clinical data presentations, financial results, development financing, and corporate updates tied to listing status and OTC quotation. Vaccinex also reports activity involving its ActivMAb® platform, which uses viral display of complex antigens to support antibody discovery collaborations and project agreements.
Vaccinex, Inc. (Nasdaq: VCNX) announced the publication of results from its CLASSICAL-Lung clinical trial, evaluating pepinemab in combination with BAVENCIO® for treating non-small cell lung cancer (NSCLC). The Phase 1b/2 trial demonstrated clinical activity and safety, with a disease control rate (DCR) of 81% among immunotherapy naïve patients and 59% among those resistant to prior therapies. The results indicate that pepinemab may enhance the efficacy of checkpoint inhibitors, especially in challenging cases including PD-L1 negative tumors. The full data set is published in Clinical Cancer Research.
Vaccinex, Inc. (Nasdaq: VCNX) reported top-line results from the SIGNAL Phase 2 study showing potential cognitive benefits of pepinemab in Huntington's disease. The company plans to initiate a Phase 1b/2 study of pepinemab with KEYTRUDA® for head and neck cancer and an Alzheimer’s trial in Q2 2021. In Q1 2021, Vaccinex raised $32 million through an open market sale agreement. Revenue increased to $625,000 in 2020, while R&D expenses decreased to $21.5 million. The company anticipates pivotal trial partnerships for Huntington’s disease and has significant funding for upcoming studies.
Vaccinex, Inc. (Nasdaq: VCNX) announced that CEO Dr. Maurice Zauderer will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, from 2:30 to 3:00 PM ET. The presentation will cover the company's innovative approach to treating cancer and neurodegenerative diseases by targeting SEMA4D. A live webcast will be available for interested investors and stakeholders. Vaccinex's lead drug candidate, pepinemab, aims to enhance immune responses against tumors while addressing chronic inflammation in the brain.
Vaccinex, Inc. (Nasdaq: VCNX) announced that Surface Oncology will license the anti-CCR8 antibody, SRF114, discovered via Vaccinex’s ActivMAb platform. The agreement entails licensing fees, research funding, development milestone payments, and royalties for Vaccinex. SRF114 targets tumor T regulatory cells, potentially enhancing immunotherapy efficacy. The ActivMAb platform has applications in discovering antibodies against complex antigens. Vaccinex's lead candidate, pepinemab, aims to treat neurodegenerative diseases by inhibiting SEMA4D, which is linked to neuroinflammation.
Vaccinex has partnered with two undisclosed pharmaceutical companies to leverage its ActivMAb® platform for antibody discovery, focusing on complex antigens like GPCRs and ion channels. These collaborations aim to enhance vaccine development and therapeutic solutions. The terms of these agreements remain undisclosed. The ActivMAb technology is known for its ability to identify unique antibodies against challenging targets, which could lead to advancements in treatment options for various diseases. Vaccinex's lead candidate, pepinemab, is also highlighted for its potential in treating neurodegenerative diseases.
Vaccinex (Nasdaq: VCNX) announced its participation in the 10th Annual LifeSci Partners Corporate Access Event from January 6-8 and 11-14, 2021. Maurice Zauderer, Ph.D., will present a corporate update and host 1x1 meetings on January 6th at 11 am EST. The company is focused on treating neurodegenerative diseases with its lead candidate, pepinemab, which inhibits SEMA4D. Pepinemab shows promise for conditions like Huntington’s and Alzheimer’s and is in trials with checkpoint inhibitors for oncology applications.
Vaccinex, Inc. (Nasdaq: VCNX) announced its financial results for Q3 2020, ending with cash and cash equivalents of $17.1 million. While the SIGNAL phase 2 trial for Pepinemab in Huntington's disease did not meet co-primary endpoints, encouraging metrics suggest further development is warranted. The company plans to initiate a Phase 1b/2 trial of Pepinemab with KEYTRUDA for head and neck cancer in H1 2021 and a Phase 1/2 study for Alzheimer's disease in 2021, with partial funding from prominent associations.
Vaccinex, Inc. (Nasdaq: VCNX) announced positive findings from its Phase 2 SIGNAL study of pepinemab in treating Huntington's disease (HD). The data suggests cognitive benefits and reduced brain atrophy in HD patients. CEO Dr. Maurice Zauderer will present the findings at the Huntington Study Group conference from October 29-31, 2020. Key analyses show significant treatment benefits and well-tolerated safety profiles, supporting further development of pepinemab for HD and other neurodegenerative diseases like Alzheimer's.
Vaccinex, Inc. (Nasdaq: VCNX) announced promising results from its Phase 2 SIGNAL trial of pepinemab for Huntington's disease (HD), presented during the Huntington Study Group conference. The data indicate significant cognitive benefits and reduced brain atrophy in HD patients treated with pepinemab. Key findings include strong improvements in the HD-Cognitive Assessment Battery and clinical assessments. The company aims to further develop pepinemab for HD and other neurodegenerative diseases. Safety data show good tolerability and low dropout rates, supporting its potential for combination therapies.
Vaccinex, Inc. (Nasdaq: VCNX) has announced a live moderated video webcast featuring management and KOL Eric Siemers, MD on October 27, 2020, at 10:00 AM EDT. The discussion will cover insights from the SIGNAL phase 2 study in Huntington’s disease, its implications for Alzheimer’s disease, and a review of the combination treatment of pepinemab with Keytruda® for Head & Neck Cancer. The event will be accessible via the Investors section of Vaccinex’s website, with a replay available two hours after the live session.